An artificial intelligence (AI) tool, the Cryosection Histopathology Assessment and Review Machine (CHARM), is showing promise in aiding doctors in the fight against aggressive brain tumors.
CHARM can quickly identify the genetic profile of a glioma tumor, a process that currently takes days or weeks, potentially improving patient outcomes and reducing the need for multiple surgeries, reported Bloomberg citing the journal Med.
CHARM: A New Hope in Glioma Treatment
CHARM uses machine learning to study images and identify the genetic profile of glioma, a type of brain tumor that can lead to death in less than six months if untreated.
The tool was trained by showing it pictures of samples gathered during brain surgery and then checking its work against those patients' diagnoses.
While not as accurate as current genetic tests, CHARM can predict a tumor's profile almost instantly, potentially allowing doctors to proceed with the right treatment without the added time of scheduling and performing another surgery.
AI in Cancer Treatment
CHARM can also distinguish malignant tumor cells from benign cells and identify a tumor's grade, a measure of how aggressive it is.
These are decisions that human pathologists can make during surgery, but the tool could remove the need for a 10-to-15-minute wait, or for a pathologist to be on standby during an operation. However, CHARM still needs to be tested in real-world settings, the researchers said.
Read Next: Full-Body MRI Scanner With AI Technology Could Be The Key To Early Cancer Detection: Benzinga
Hi, I am the Benzinga Newsbot! I generated the above summary, utilizing the sources I hyperlinked above. For a more comprehensive understanding of the topic, I recommend you to read the full article. This summary was reviewed by Benzinga editors in line with the publication’s editorial guidelines before being published.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
